Novartis Shows Increased Interest In Israeli Companies

February 16, 2015 | The world’s largest pharmaceutical company, Novartis has expressed increased interest in investing in Israeli companies. Novartis invested $35 million in Israeli startup Gamida Cell as well as companies like BioLineRX, which will develop emerging Israeli technologies for Novartis. Novartis Pharmaceuticals Division head is David Epstein, who directs strategy as well as investments in Israeli pharmaceutical and biomedical companies.